Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has big plans for the combo therapy. Read More
The EMA’s Committee for Medicinal Products for Human Use recommended 17 drugs for approval at its December meeting, bringing the total for 2024 to 114. That is up from the 77 drugs recommended for approval in 2023, of which 39 were novel. Read More
Beigene Ltd. struck a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. worth up to $1.5 billion for its phase I selective methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH-2039, which is being explored for solid tumors. Read More
Mixed results for three of Bicycle Therapeutics plc’s zelenectide pevedotin development programs preceded a strong drop in the company’s stock. Bicycle shares (NASDAQ:BCYC) dropped 31.3% on Dec. 13 to close at $13.81 each, the stock’s lowest price in the past 12 months. Read More
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for degradation. “Insulin was discovered 100 years ago, and the insulin receptor was discovered 50 years ago,” Heiko Lickert told BioWorld. “Now we have a new insulin receptor, which degrades insulin.” Lickert is the senior author of the paper reporting the new insights into how inceptor works, which were published online in Nature Metabolism. Read More
GC Biopharma Corp. will buy plasma collector Abo Holdings Inc. in a ₩138 billion (US$96.28 million) cash acquisition as the vaccine and plasma-derived medicinal products developer works to accelerate entry of Alyglo (IVIG-SN 10%) in the U.S., where it was approved last year. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Blue Lake, Briacell, Caliway, Corcept, Eli Lilly, Halia, Immutep, Keros, Kiromic, Krystal, Merck, Ose Immunotherapeutics, Pfizer. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acadia, Agenus, Concertai, Conduit, Dapu, Dewpoint, Elevation, Enable Medicine, Fonseca, General Inception, Kineta, Leveragen, Merlion, Neuraxpharm, Peptidream, Pharmathen, Synaffix, Tanner, Tuhura. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: DBV, Hutchmed, Immuneering, Neurosense, Novonordisk, SK Bioscience, Sobi. Read More
